Sildenafil and Uteroplacental Perfusion

Phase 2 Study of Fetal Growth Retardation Treatment by Sildenafil

The purpose of this study is to determine whether sildenafil is effective and safe in the treatment of fetal growth restriction.

Fetal growth retardation affects up to 8% of all pregnancies and has massive short term (increased fetal morbidity and mortality) and long-term (increased incidence of cardiovascular disorders in adulthood) health implications.

Doppler waveform analysis of these pregnancies suggests compromised uteroplacental circulation and placental hypoperfusion.

Our aim is to assess if sildenafil citrate could improve vasodilatation in FGR pregnancies.

Sildenafil citrate may offer a potential therapeutic strategy to improve uteroplacental perfusion in FGR.

Animal studies suggest that phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil citrate, may improve uterine blood flow .

Inclusion Criteria:

• FGR pregnancies in 24-37 weeks of GA

Exclusion Criteria:

• vasodilator agents usage
• history of cardiovascular morbidity specially of right heart side
• drug or alcohol abusers
• systolic BP more than 210 mm Hg or diastolic BP more than 120 mm Hg